![]() |
<< Back |
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting |
“As we continue our mission to improve the understanding of rare genetic disorders of obesity and develop a potentially transformative therapy for people who currently have no treatment options, we are encouraged by our longer-term data with setmelanotide, which show that patients who have been on treatment for many months continue to experience sustained improvements in body weight and appetite,” said BBS and Alström Syndrome are life-threatening, ultra-rare orphan diseases that are closely related. Both cause severe obesity and insatiable hunger, also known as hyperphagia, that often present during childhood. BBS affects approximately one in 100,000 people in Setmelanotide is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist that is being developed by Rhythm for the treatment of rare genetic disorders of obesity. Updated Data Presented at 57th Annual ESPE Meeting In an oral presentation,
A separate poster reported updated data on body weight, hunger scores, and the safety of treatment with setmelanotide in one patient with Alström Syndrome as of
About Setmelanotide Setmelanotide is a potent, first-in-class, melanocortin-4 receptor (MC4R) agonist in development for the treatment of rare genetic disorders of obesity. Setmelanotide activates MC4R, part of the key biological pathway that independently regulates energy expenditure and appetite. Variants in genes within the MC4R pathway are associated with unrelenting hunger and severe, early-onset obesity. Rhythm is currently developing setmelanotide as a replacement therapy for patients with monogenic defects upstream of MC4R, for whom there are no effective or approved therapies. About Rhythm Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm is currently evaluating the efficacy and safety of setmelanotide, the Company’s first-in-class melanocortin-4 receptor (MC4R) agonist, in Phase 3 studies in patients with pro-opiomelanocortin (POMC) deficiency obesity (which includes deficiencies in both the POMC and PCSK1 genes) and leptin receptor (LEPR) deficiency obesity. Rhythm also supports Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements regarding Rhythm's expectations regarding its anticipated timing for initiation and enrollment for clinical trials, and the development of a potentially transformative therapy. Statements using word such as "expect", "anticipate", "believe", "may", "will" and similar terms are also forward looking statements. Such statements are subject to numerous risks and uncertainties, including but not limited to, our ability to enroll patients in clinical trials, the outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, and expenses, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports we file with the Investor Contact: Media Contact:
|
